Prostate Cancer (PC) is a type of cancer that is often diagnosed at very early stages due to improved detection among man in the Western world. Current imaging techniques are not optimal to determine extent of minimal early stage PC even though this is of great clinical importance. Human PC and high-grade PIN have shown high Gastrin-Releasing Peptide Receptor (GRPR) expression, while normal prostate tissue and BPH revealed to be predominantly GRPR-negative. Radiolabelled Gastrin-Releasing Peptide (GRP) or bombesin (BN) analogues targeting the GRPR can be used as non-invasive tools to diagnose, monitor and potentially treat PC. These BN analogues have already proven to be able to image PC in both tumour-bearing mice and clinical patients showing no important side effects. It's desirable that new peptides require fast-track standardised comparative testing in relevant PC models to select the best performing BN analogues for further evaluation in patients. Although knowledge about GRPR expression and development of new BN analogues can be extended, it is time to study performance of BN analogues for peptide receptor based imaging in patients validating results of PC imaging using histopathology as a golden standard.

Additional Metadata
Keywords Bombesin, Gastrin-Releasing Peptide, Peptide receptor imaging, Prostatic neoplasms
Persistent URL dx.doi.org/10.1016/j.ymeth.2009.04.002, hdl.handle.net/1765/25935
Journal Methods
Citation
Schroeder, R.P.J, van Weerden, W.M, Bangma, C.H, Krenning, E.P, & de Jong, M. (2009). Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods (Vol. 48, pp. 200–204). doi:10.1016/j.ymeth.2009.04.002